OSUR icon

OraSure Technologies

3.64 USD
-0.15
3.96%
At close Dec 20, 4:00 PM EST
After hours
3.64
+0.00
0.00%
1 day
-3.96%
5 days
-7.14%
1 month
-4.46%
3 months
-15.94%
6 months
-19.82%
Year to date
-56.04%
1 year
-53.63%
5 years
-56.92%
10 years
-65.37%
 

About: OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

Employees: 638

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5% less capital invested

Capital invested by funds: $297M [Q2] → $283M (-$14M) [Q3]

8% less call options, than puts

Call options by funds: $22K | Put options by funds: $24K

5.39% less ownership

Funds ownership: 94.45% [Q2] → 89.06% (-5.39%) [Q3]

11% less funds holding

Funds holding: 210 [Q2] → 187 (-23) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 70

46% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 50

Research analyst outlook

We haven’t received any recent analyst ratings for OSUR.

Financial journalist opinion

Based on 4 articles about OSUR published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
OraSure Technologies Acquires Sherlock Biosciences
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
OraSure Technologies Acquires Sherlock Biosciences
Positive
Seeking Alpha
1 week ago
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation.
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Neutral
GlobeNewsWire
2 weeks ago
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
Positive
Zacks Investment Research
3 weeks ago
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
Neutral
GlobeNewsWire
1 month ago
OraSure to Participate in Upcoming Investor Conference
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
OraSure to Participate in Upcoming Investor Conference
Positive
Zacks Investment Research
1 month ago
Is OraSure Technologies (OSUR) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is OraSure Technologies (OSUR) a Great Value Stock Right Now?
Neutral
Seeking Alpha
1 month ago
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.27 per share a year ago.
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
OraSure Reports Q3 '24 Revenue of $39.9 Million
Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2024.
OraSure Reports Q3 '24 Revenue of $39.9 Million
Neutral
Seeking Alpha
1 month ago
OraSure: An NCAV Diamond In The COVID Rough
OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value (NCAV). At the same time, OraSure has a stable operational history with consistent normalized cash flow margins.
OraSure: An NCAV Diamond In The COVID Rough
Charts implemented using Lightweight Charts™